Hier finden Sie wissenschaftliche Publikationen aus den Fraunhofer-Instituten.

Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function

: Waschki, Benjamin; Watz, Henrik; Holz, Olaf; Magnussen, Helgo; Olejnicka, Beata; Welte, Tobias; Rabe, Klaus F.; Janciauskiene, Sabina

Fulltext urn:nbn:de:0011-n-4525202 (419 KByte PDF)
MD5 Fingerprint: 4510d17404c8245140a9ef11fecead72
(CC) by-nc
Created on: 20.6.2017

International journal of chronic obstructive pulmonary disease 12 (2017), pp.981-987
ISSN: 1176-9106
ISSN: 1178-2005
Journal Article, Electronic Publication
Fraunhofer ITEM ()
N-terminal pro-B-type natriuretic peptide; ankle-brachial index; cardiovascular disease; chronic obstructive pulmonary disease; Hypertriglyceridemia; inflammation; plasminogen activator inhibitor-1

INTRODUCTION: Plasminogen activator inhibitor-1 (PAI-1), a major inhibitor of fibrinolysis, is associated with thrombosis, obesity, insulin resistance, dyslipidemia, and premature aging, which all are coexisting conditions of chronic obstructive pulmonary disease (COPD). The role of PAI-1 in COPD with respect to metabolic and cardiovascular functions is unclear.
METHODS: In this study, which was nested within a prospective cohort study, the serum levels of PAI-1 were cross-sectionally measured in 74 stable COPD patients (Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stages I-IV) and 18 controls without lung disease. In addition, triglycerides, high-density lipoprotein cholesterol, fasting plasma glucose, waist circumference, blood pressure, smoking status, high-sensitive C-reactive protein (hs-CRP), adiponectin, ankle-brachial index, N-terminal pro-B-type natriuretic peptide, and history of comorbidities were also determined.
RESULTS: The serum levelsof PAI-1 were significantly higher in COPD patients than in controls, independent of a broad spectrum of possible confounders including metabolic and cardiovascular dysfunction. A multivariate regression analysis revealed triglyceride and hs-CRP levels to be the best predictors of PAI-1 within COPD. GOLD Stages II and III remained independently associated with higher PAI-1 levels in a final regression analysis.
CONCLUSION: The data from the present study showed that the serum levels of PAI-1 are higher in patients with COPD and that moderate-to-severe airflow limitation, hypertriglyceridemia, and systemic inflammation are independent predictors of an elevated PAI-1 level. PAI-1 may be a potential biomarker candidate for COPD-specific and extra-pulmonary manifestations.